Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1989 2
1990 1
1991 2
1993 3
1994 1
1995 4
1996 2
1997 2
1998 1
1999 8
2000 6
2001 4
2002 3
2003 6
2004 15
2005 12
2006 12
2007 15
2008 23
2009 16
2010 12
2011 16
2012 13
2013 18
2014 18
2015 13
2016 10
2017 13
2018 15
2019 17
2020 17
2021 21
2022 23
2023 22
2024 16
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Appel GB, et al. J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15. J Am Soc Nephrol. 2009. PMID: 19369404 Free PMC article. Clinical Trial.
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. Kalunian KC, et al. Among authors: manzi s. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369793 Free PMC article. Clinical Trial.
Recommendations for the Management of Initial and Refractory Pediatric Status Dystonicus.
Vogt LM, Yang K, Tse G, Quiroz V, Zaman Z, Wang L, Srouji R, Tam A, Estrella E, Manzi S, Fasano A, Northam WT, Stone S, Moharir M, Gonorazky H, McAlvin B, Kleinman M, LaRovere KL, Gorodetsky C, Ebrahimi-Fakhari D. Vogt LM, et al. Among authors: manzi s. Mov Disord. 2024 Sep;39(9):1435-1445. doi: 10.1002/mds.29794. Epub 2024 Apr 15. Mov Disord. 2024. PMID: 38619077 Review.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Petri M, et al. Among authors: manzi s. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473. Arthritis Rheum. 2012. PMID: 22553077 Free PMC article.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, Lawrence Ford T, Gupta R, Hiepe F, Santiago M, Brohawn PZ, Berglind A, Tummala R; TULIP-1 study investigators. Furie RA, et al. Among authors: manzi s. Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11. Lancet Rheumatol. 2019. PMID: 38229377
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations.
Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall'Era M, Adelowo O, Bae SC, Beretta L, Bonfa E, Cervera R, Chasset F, Clarke AE, Costedoat-Chalumeau N, Doria A, Espinosa G, Fanouriakis A, Fredi M, Gatto M, Gladman DD, Gomez-Puerta JA, Inanç M, Ines LS, Isenberg D, Izuka S, Khmelinskii N, Legge A, Macieira C, Monticielo OA, Morand EF, Muñoz-Louis R, Padjen I, Petri M, Piga M, Pons-Estel BA, Ramirez GA, Ramsey-Goldman R, Richez C, Sciascia S, Toro-Gutierrez CE, Van Vollenhoven RF, Vital EM, Gerosa M, Touma Z, Mosca M, Tani C; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. Arnaud L, et al. Lancet Rheumatol. 2025 Jul;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3. Epub 2025 May 23. Lancet Rheumatol. 2025. PMID: 40418946 Review.
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes.
Choi MY, Chen I, Clarke AE, Fritzler MJ, Buhler KA, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon JP, Sontag D, Costenbader KH. Choi MY, et al. Among authors: manzi s. Ann Rheum Dis. 2023 Jul;82(7):927-936. doi: 10.1136/ard-2022-223808. Epub 2023 Apr 21. Ann Rheum Dis. 2023. PMID: 37085289 Free PMC article.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Vital EM, et al. Among authors: manzi s. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. Ann Rheum Dis. 2022. PMID: 35338035 Free PMC article. Clinical Trial.
The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. Hanly JG, et al. Among authors: manzi s. Rheumatology (Oxford). 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5. Rheumatology (Oxford). 2016. PMID: 26342222 Free PMC article.
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.
Morand EF, van Vollenhoven R, Furie RA, Kalunian KC, Manzi S, Abreu G, Tummala R, Duncan EA, Al-Mossawi H, Lindholm C. Morand EF, et al. Among authors: manzi s. Ann Rheum Dis. 2025 May;84(5):777-788. doi: 10.1016/j.ard.2025.01.016. Epub 2025 Jan 30. Ann Rheum Dis. 2025. PMID: 39948001 Free article. Clinical Trial.
359 results